Bioretec Oy

Bioretec Oy EBIT per Share

The EBIT per Share of Bioretec Oy (BRETEC.HE) as of Nov 5, 2026 is -0.03 EUR. In the previous year, EBIT per Share was -0.02 EUR — a change of 63.57% (lower).

EBIT per Share

-0.03EUR

YoY

63.57%

Last updated:

EBIT per Share of Bioretec Oy is 2025 -0.03 EUR. EBIT per Share of Bioretec Oy was 2024 -0.02 EUR. It decreases by 63.57% lower compared to the previous year.

The Bioretec Oy EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2021
-0.00 EUR
Jan 1, 2022
-0.16 EUR
Jan 1, 2023
-0.16 EUR
Jan 1, 2024
-0.02 EUR
Jan 1, 2025
-0.03 EUR
Jan 1, 2026 (e)
-0.02 EUR
Jan 1, 2027 (e)
-0.02 EUR
Jan 1, 2028 (e)
0.00 EUR
The Bioretec Oy EBIT per Share history
YEAREBIT per ShareYoY
est0.00EUR-100.00%
est-0.02EUR-29.22%
est-0.02EUR-10.46%
-0.03EUR+63.57%
-0.02EUR-90.00%
-0.16EUR-2.38%
-0.16EUR+8,073.39%
-0.00EUR+38.50%
-0.00EUR+10.79%
-0.00EUR-98.92%
-0.12EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioretec Oy Stock analysis

What does Bioretec Oy do? Bioretec Oy develops bioabsorbable and bioresorbable implants for pediatric and adult orthopaedics, operating as a developer, manufacturer, and commercializer of innovative bioresorbable orthopedic implants and implant materials. The company's Activa product portfolio includes bioabsorbable biopolymer products available in the market for pediatric, trauma, and sports surgery applications. Bioretec Oy has a Germany-based subsidiary, BRI.Tech GmbH, and its products are used globally across various medical specialties. The company generates revenue through the sale of its Activa product portfolio, targeting healthcare providers and medical institutions worldwide. The Activa products are designed for bone and soft tissue injury treatments, serving segments in pediatrics, trauma surgery, and sports medicine. Bioretec Oy's global distribution network enables the commercialization of its implants in international markets. Bioretec Oy's business model focuses on the development, manufacturing, and commercialization of bioresorbable orthopedic solutions. The company's products are marketed under the Activa brand, catering to medical professionals in specialized surgical fields. The Germany-based subsidiary BRI.Tech GmbH supports the company's operations in the European market. Bioretec Oy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioretec Oy stock

EBIT per Share of Bioretec Oy is -0.03 EUR in 2025.

EBIT per Share of Bioretec Oy changed from -0.02 EUR to -0.03 EUR, representing a 63.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Bioretec Oy since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Bioretec Oy

All Key Metrics — Bioretec Oy